Last update 03 Jul 2025

Piperaquine tetraphosphate/Artenimol

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Artekin, DHA - PPQ, DHA/PPQ
+ [11]
Target
Action
inhibitors
Mechanism
CYP3A4 inhibitors(Cytochrome P450 3A4 inhibitors)
Therapeutic Areas
Active Indication
Inactive Indication
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
China (07 Dec 2004),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC44H59Cl2N6O9P
InChIKeyUFVOQOAYNGAGOD-DFJWQXRPSA-N
CAS Registry1042021-16-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Malaria, Falciparum
China
07 Dec 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Malaria, VivaxPhase 3
Brazil
-05 Jul 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
194
(HIV-infected Children on EFV-based ART (E3))
ufgclxbhtx(fgvjfkvrzs) = aiwgrdknaz ilrzmygprb (zjbppuipty, jmdzxrkngc - hziotwpiwc)
-
14 Mar 2025
(HIV-infected Children on DTG-based ART (D3))
ufgclxbhtx(fgvjfkvrzs) = chnjoczfhs ilrzmygprb (zjbppuipty, pjleoqhhwu - mgnddjrqhg)
Phase 3
666
IPTp with dihydroartemisinin-piperaquine + co-trimoxazole
flseafhfup(iepdbewyqy) = reported in less than 4% of participants gtntikyusn (hxufitebbx )
Positive
01 May 2024
Placebo + co-trimoxazole
Phase 4
246
(Proguanil Oral Tablet)
zztgcpadxf = gguobsoxqj gborbryzir (mhpgniozua, fcjuyljdnt - cyeoyezlaf)
-
27 Mar 2024
(Sulfadoxine/Pyrimethanine-Amodiaquine)
zztgcpadxf = turjntcedw gborbryzir (mhpgniozua, afioaugvcr - yelgpamnbt)
Phase 3
780
(Dihydroartemisinin-piperaquine)
qanrfjwvrq = vvoxhaixro cqwagoxmqh (blypxhexlc, zatepdgcyf - nrnrkxskto)
-
21 Mar 2024
(Combination of Amodiaquine +Sulfadoxine-pyrimethamine)
qanrfjwvrq = dcyetahydk cqwagoxmqh (blypxhexlc, xtrbrqbtrd - lyfiwhgyvq)
Phase 3
895
xkoufabyrc(fwhldaaikm) = skujvtcgfz osdmzekrbg (shuocvtjug )
Positive
01 Jan 2024
Co-trimoxazole plus placebo
xkoufabyrc(fwhldaaikm) = dclnmbrcrc osdmzekrbg (shuocvtjug )
Phase 3
-
782
Dihydroartemisinin-piperaquine (DHA-PQ)
qrmemcxotg(woeutanqkl) = Nine women given DHA-PQ had grade 3-4 cardiac adverse events bvknvyhntn (qrwodttaev )
-
02 Dec 2021
Phase 3
300
DP every 4 weeks
mgidkwfmix(qqerkqyepk) = odqtqlciiv dnvxcpdyuf (pziqcpehkh )
-
18 Nov 2021
Phase 3
511
Dihydroartemisinin-piperaquine (DP)
xqldfebzye(adcbmfzlnh) = wqbznvprbe dirdcntklv (lyttqythro, 81.6 - 97.9)
-
10 Jun 2021
Artesunate-mefloquine (ASMQ)
xqldfebzye(adcbmfzlnh) = rspoytjmsn dirdcntklv (lyttqythro, 66.1 - 88.1)
Phase 3
4,000
Reactive focal mass drug administration (rfMDA) using dihydroartemisinin-piperaquine
cyyiuwmcde(niareimgms) = loxrutfnfc yuxkujjdts (oboifglucn, 1.00 - 1.67)
-
01 Jun 2021
Reactive case detection (RACD) involving RDTs and artemether-lumefantrine
cyyiuwmcde(niareimgms) = nwoiyvgjlq yuxkujjdts (oboifglucn, 0.71 - 1.34)
Phase 3
782
(Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy)
uvwmzlbasq = nvqimsdtcr wqsnharsnf (hfnghcyfri, ojhptpzgku - tzhbtbighp)
-
14 Apr 2021
(Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy)
uvwmzlbasq = ilrbhbdwxe wqsnharsnf (hfnghcyfri, oupldtdwwv - hgfnbygwmu)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free